Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, March 2000, p. 665-675, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Apoptosis in Renal Proximal Tubules of Rats Treated
with Low Doses of Aminoglycosides
Mohammed
El Mouedden,1
Guy
Laurent,2
Marie-Paule
Mingeot-Leclercq,1
Henryk S.
Taper,3
Jean
Cumps,4 and
Paul M.
Tulkens1,*
Unités de Pharmacologie Cellulaire et
Moléculaire,1 de
Pharmacocinétique, Métabolisme, Nutrition et
Toxicologie,3 et de Chimie
Pharmaceutique et Radiopharmacie,4
Université Catholique de Louvain, B-1200 Brussels, and
Service d'Histologie et de Cytologie Expérimentale,
Université de Mons-Hainaut, B-7000 Mons,2
Belgium
Received 19 August 1999/Returned for modification 1 December
1999/Accepted 20 December 1999
 |
ABSTRACT |
Kidney cortex apoptosis was studied with female Wistar rats treated
for 10 days with gentamicin and netilmicin at daily doses of 10 or 20 mg/kg of body weight and amikacin or isepamicin at daily doses of 40 mg/kg. Apoptosis was detected and quantitated using cytological (methyl
green-pyronine) and immunohistochemical (terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling)
staining, in parallel with a measurement of drug-induced phospholipidosis (cortical phospholipids and phospholipiduria), cortical proliferative response (3H incorporation in DNA
and histoautoradiography after in vivo pulse-labeling with
[3H]thymidine), and kidney dysfunction (blood urea
nitrogen and creatinine). Gentamicin induced in proximal tubules a
marked apoptotic reaction which (i) was detectable after 4 days
of treatment but was most conspicuous after 10 days, (ii) was dose
dependent, (iii) occurred in the absence of necrosis, and (iv) was
nonlinearly correlated with the proliferative response (tubular and
peritubular cells). Comparative studies revealed a parallelism among
the extents of phospholipidosis, apoptosis, and proliferative
response for three aminoglycosides (gentamicin >> amikacin
isepamicin). By contrast, netilmicin induced a marked phospholipidosis
but a moderate apoptosis and proliferative response. We
conclude that rats treated with gentamicin develop an apoptotic
process as part of the various cortical alterations induced by this
antibiotic at low doses. Netilmicin, and still more amikacin and
isepamicin, appears safer in this respect. Whereas a relation between
aminoglycoside-induced tubular apoptosis and cortical
proliferative response seems to be established, no simple correlation
with phospholipidosis can be drawn.
 |
INTRODUCTION |
Aminoglycosides have long been and
still are an essential component of our armamentarium against severe,
life-threatening infections caused by gram-negative bacilli (20,
49). Their nephrotoxicity and ototoxicity, however, remain of
concern to clinicians, even though the optimization of their mode of
administration (21) and the use of intrinsically less toxic
derivatives (48) already offer some increased safety. An
intriguing aspect of aminoglycoside nephrotoxicity remains the fact
that very large amounts of drug (usually 10 times the therapeutic
doses) must be administered to animals in order to cause clear-cut
acute tubular necrosis and concomitant alteration of the renal function
(20, 52). In contrast, rats treated with low, more
therapeutically relevant dosages show neither extended tubular necrosis
nor gross kidney dysfunction but merely an array of alterations
involving the apical and basolateral membrane, the lysosomes, and
various other subcellular components of proximal tubule cells, none of
which, however, has unambiguously been associated with cell death and
organ dysfunction (49). Yet, the development of these
alterations is associated with an increased tissue DNA synthesis, which
develops in parallel with the appearance of dedifferentiated cells in
the proximal tubules and a proliferation of interstitial cells
(38, 67). It has long been thought that this process was a
reaction to focal tubular necroses (39), which are difficult
to quantitatively assess because dead cells are quickly swept away in
the lumen and the urine. Based on nonsystematic morphological
observations performed during our early studies, however, we suggested
that gentamicin could also induce the apoptotic death of
epithelial tubular cells (38), but the importance of this
phenomenon was not examined. Apoptosis, or programmed cell death, was
originally described in the study of insect tissue degeneration
(43) and was later found to be a prominent process in most
instances of tissue remodeling (33). It designates a form of
cell demise characterized by specific cytological features which make
it quite distinct from necrosis, such as cell shrinkage, increased
cytoplasmic density, and compaction of chromatin which segregates into
well-defined clumps abutting the nuclear membrane (10).
While apoptosis is a physiological process during embryogenesis
and the establishment of immune self-tolerance (1, 44, 73),
it can also be triggered by various pharmacological agents, including
anticancer drugs (74) and antibiotics (2). The
ototoxicity of aminoglycosides has been attributed to apoptosis
of cochlear and vestibular hair cells in the inner ear sensory
epithelia (36, 50). The recognition that apoptosis
entails the cleavage of internucleosomal DNA (DNA laddering) by
endogenous endonucleases such as caspase-activated endonuclease (CAD)
(16), has led to the development of immunohistochemical techniques allowing one to easily observe and quantitate the occurrence of apoptotic cells in tissue sections (19). This
offered a valuable opportunity to reexamine our original suggestion
that gentamicin causes apoptosis in kidney tissues. We
therefore present here a quantitative evaluation of apoptosis
induced in renal cortex by gentamicin at low, therapeutically relevant
doses in correlation with the development of other early, subclinical
tissue alterations. Netilmicin, amikacin, and isepamicin have been
included to better assess the significance of our findings in relation
to the lower nephrotoxic potential of these derivatives
(48).
(Preliminary accounts of this work have been given at the 35th and the
38th Interscience Conference on Antimicrobial Agents and Chemotherapy
[M. El Mouedden, H. Taper, G. Laurent, and P. M. Tulkens, Abstr.
35th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-123, 1995, and M. El Mouedden, G. Laurent, M. P. Mingeot-Leclercq, and
P. M. Tulkens, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-88, 1998, respectively].)
 |
MATERIALS AND METHODS |
Overall design of the experiments.
The administration of low
doses of gentamicin (typically 4 to 10 mg/kg of body weight) is known
to cause within 10 days in renal proximal tubular cells (i) the
development of a conspicuous lysosomal phospholipidosis which can be
assessed directly by the measurement of total cortical phospholipids
(37), and indirectly by the determination of
phospholipiduria (27, 28, 32) and (ii) a significant
cellular proliferation which can be visualized and quantitated by
histoautoradiography and measurement of DNA radioactivity in
[3H]thymidine-pulsed animals (38). Tubular
necroses become clearly detectable only at larger doses (20 mg/kg or
more [52]). The severity of the lysosomal alterations
and the extent of cellular proliferation at low doses and of the
cortical necrosis and the kidney dysfunction at large doses are
increased if the daily dose of the aminoglycosides is divided into two
or three administrations over 24 h (P. M. Tulkens, M. E. De Broe, P. Maldague, G. Verpooten, and S. Scharpe, Abstr. Annu. Meet.
Am. Soc. Microbiol. 1982, abstr. A 30, 1982; 6, 38).
Based on these considerations, on previous studies with aminoglycosides
(53, 69, 72), and on pilot studies, we selected the
experimental conditions defined in Table 1. These were aimed at providing an
appropriate model of the clinical use of aminoglycosides and at
mimicking as much as possible the actual drug exposure experienced by
patients. Moreover, the doses, treatment duration, and schedules used
were known by us to elicit a frank phospholipidosis in the absence of
visible tubular necrosis at the lower dose and detectable tubular
necrosis at the higher dose. Netilmicin was systematically compared to
gentamicin throughout these experiments since it causes a marked
phospholipidosis (69) but less necrosis than does gentamicin
(53). The comparison was thereafter extended to amikacin and
isepamicin, both of which cause a mild phospholipidosis and little
necrosis (69, 72).
Animals and treatments.
All studies were performed with
female Wistar rats (180 to 200 g in body weight) purchased from a
commercial breeding farm (Iffa-Credo, l'Arbresle, France). Before and
during treatment, animals were housed in a central facility submitted
to a 12-h light-dark cycle, provided with regular rat chow and tap
water ad libitum, and handled and treated according to the guidelines of the Belgian Ministry of Agriculture (agreement no. LA 12303116). Twenty-four hours before termination of the treatment, the rats were
transferred to metabolic cages designed for urine collection. All daily
doses (see data) were split into halves given as two separate
administrations at around 9 a.m. and 5 p.m., respectively. Drugs were injected by the intraperitoneal route after appropriate dilution in 0.9% NaCl in order to deliver a volume of 0.5 ml per 200 g of animal and per injection (the actual volume injected into
each rat was adjusted according to the body weight which was recorded
immediately before each drug administration). For control animals, only
0.9% NaCl (0.5 ml per 200 g of animal) was administered. Each
experimental group, including controls, contained six animals. Treated
and control rats were killed approximately 16 h after the last
drug injection and exactly 1 h after intraperitoneal injection of
200 µCi of [methyl-3H]thymidine (40 Ci/mmol;
Amersham International plc, Little Chalfont, United Kingdom).
Sacrifice and sampling of renal tissue.
Animals were killed
by decapitation, and blood samples were collected from the stump for
the measurement of serum creatinine and blood urea nitrogen (BUN). Both
kidneys were exposed by laparotomy and excised. After longitudinal
bisection, the renal cortex was removed by sharp dissection. For light
microscopy studies, two necropsy specimens (each equivalent to
approximately a quarter of each kidney) were fixed separately in
Carnoy's mixture and in 10% neutral buffered formalin (4.2%
formaldehyde) at room temperature for 24 and 48 h, respectively.
The remaining renal cortex tissue was snap-frozen in dry ice and stored
at
80°C until biochemical analysis.
Morphological studies. (i) Histological demonstration of
apoptotic cells.
Kidney specimens, fixed in formalin or
Carnoy's mixture, were dehydrated in graded ethanol solutions and
embedded in paraffin. Sections (approximately 7 µm thick) of
formalin-fixed tissue were used for hematoxylin-eosin staining or
terminal deoxynucleotidyltransferase (TdT)-mediated dUTP-biotin nick
end labeling (TUNEL), whereas other sections (also approximately 7 µm
thick) from tissue fixed in Carnoy's mixture were stained with methyl
green-pyronine according to the method of Brachet (8).
(ii) Immunohistochemical demonstration of apoptosis.
Apoptotic cells were detected by TdT-mediated extension of 3' OH ends
of fragmented DNA using either digoxigenin- or fluorescein-labeled dUTP
as a precursor (TUNEL) (this method is an adaptation from the original
work of Gavrieli et al. [19], who used biotin-labeled dUTP). DNA-bound digoxigenin or fluorescein was revealed by reaction with antidigoxigenin or antifluorescein antibodies labeled with peroxidase. Reagents were purchased as commercial kits (Apoptag; Oncor,
Gaithersburg, Md.; in situ cell death detection kit POD; Boehringer
Mannheim, Mannheim, Germany [presently Roche Diagnostics]). The
immunohistochemical staining procedure was carried out in accordance
with the suppliers' recommendations. Briefly, sections of
formalin-fixed and paraffin-embedded specimens were dewaxed, rehydrated, and pretreated with 20 µg of proteinase K per ml for 15 min at room temperature. After rinsing, the sections were incubated for
2 h in a reaction buffer containing TdT, dATP, and
digoxigenin-11-dUTP or fluorescein-11-dUTP. At the end of the
incubation, the sections were rinsed with a stop-wash buffer for 30 min
at 37°C, and the mixture was then replaced by peroxidase-conjugated
antidigoxigenin or antifluorescein antibody. Immunocomplexes were
visualized by exposure to H2O2 and
diaminobenzidine. Finally, sections were counterstained with methyl
green prior to mounting for light microscopy examination. Two positive
controls were made to check that the immunostaining performed under our
experimental conditions specifically revealed nuclei containing
fragmented DNA. For the first one, DNA nicking was produced by exposing
sections of control kidneys to micrococcal nuclease (10 µg/ml, 10 min, 37°C). In the second one, apoptosis was induced in
cultured thymocytes by exposure to dexamethasone (3, 19). In
both cases, we clearly observed the appearance of a large number of
immunostained nuclei. Negative controls were also run by omitting the
addition of TdT in the reaction mixture. No labeling was seen in this
case in both kidney sections and smears of dexamethasone-treated thymocytes.
(iii) Morphological demonstration of cell proliferation.
S-phase cells were detected by histoautoradiography as described in the
work of Laurent et al. (38). Paraffin sections were dewaxed
and coated in the dark by dipping them in K-5 Ilford nuclear emulsion
(Ilford Ltd., Mobberley, Cheshire, United Kingdom).
Histoautoradiographs, stored at 4°C in sealed boxes, were allowed 5 weeks for proper exposure. After processing, tissue sections were
counterstained with hemalun and eosin.
(iv) Quantitative analyses.
Enumeration of labeled nuclei
(TUNEL histological or histoautoradiography) was performed for slides
picked at random for each experimental animal (three slides for Brachet
staining; two slides for apoptosis immunolabeling and
histoautoradiography). These slides were assigned an arbitrary code
which was disclosed to the observer (M.E.) only after final pooling of
the results. Examination was made on a Zeiss light microscopy at ×40
magnification for the enumeration of S-phase cells and at ×40 or ×63
magnification for apoptotic nuclei. For calibration purposes, a
square grid was mounted in one eyepiece, determining a square field of
0.04 or 0.016 mm2, depending on the magnification. The
number of fields examined per slide was 20 for the methyl
green-pyronine-stained sections and the immunostained sections and 40 for the histoautoradiographs (yielding total surfaces of 0.966, 0.644, and 3.22 mm2 per slide, respectively). For the histological
assessment of apoptosis, we counted all cells with a pyknotic
and karyorrhectic nucleus (typically, the total numbers of nuclei
actually counted per animal were
3 for controls and
60 and
100
for rats treated for 10 days with 10 and 20 mg of gentamicin per kg,
respectively). For the assessment of apoptosis by TUNEL, we
counted all nuclei exhibiting a frank brown labeling. These nuclei most
often displayed typical alterations such as pyknosis, crescent-like
condensation of the chromatin, or formation of apoptotic
bodies. Clusters of apoptotic bodies were given a single count
(typical numbers of TUNEL-positive nuclei counted per animal, including
clusters of apoptotic bodies, were
2 for controls and
65
and
130 for rats treated with 10 and 20 mg of gentamicin per kg for
10 days, respectively). For the assessment of DNA synthesis by
histoautoradiography, we counted all cells with clearly recognizable
silver grains over or closely associated with the nucleus (typical
numbers of positive cells counted per animal were
6 for controls and
176 and
460 for animals receiving 10 and 20 mg of gentamicin per
kg for 10 days, respectively).
Biochemical and microbiological studies.
Cortical tissue
samples were thawed and homogenized at 0°C in distilled water for
measurement of their contents in total lipid phosphorus and protein,
using well-established procedures (5, 7, 45) which were
fully validated in the present study (coefficients of variation of 1.5 and 1.8% for the assays of tissue phospholipids and tissue proteins,
respectively [n = 20 in each case]). The same samples
were then used for the determination of DNA specific radioactivity
(38), with a minimum of 1,000 counts recorded over
background per vial. The urine collected during the 24 h preceding
the sacrifice was carefully mixed and stored at
20°C until
analysis. Samples were thawed, mixed thoroughly, and centrifuged at
25,000 rpm (Rotor 30; Beckman Instruments, Palo Alto, Calif.) for
1 h. The resulting pellets were resuspended in 1 ml of distilled water and used for the determination of total lipid phosphorus, as
detailed previously (27, 28, 34). The coefficient of variation of this determination was 4.7% (n = 20).
Serum creatinine and BUN were determined by the routine procedures
(4, 15, 31) used for human clinical samples in our
University Hospital (Cliniques Universitaires Saint-Luc, Brussels,
Belgium), with intrarun and interrun coefficients of variations of 0.6 and 1.2, and 3 and 2.5%, respectively (Hitachi 717 autoanalyzer;
Hitachi Ltd., Chiyoda-ku, Tokyo, Japan). The aminoglycoside content of the renal cortex tissue was assayed by a plate diffusion bioassay, using Bacillus subtilis (ATCC 6633) as the test organism,
using the technique developed earlier for cultured cell extracts
(68). All samples were assayed in triplicate against a
series of known standards (extracts from control animals spiked with
the corresponding antibiotic after homogenization; no interference of
homogenate protein was noted) over a 2.5- to 20-µg/ml range (typical
r
0.987) and covering the range of drug
concentrations found in the samples from treated animals.
Statistical analyses.
The statistical analysis was performed
according to a two-step procedure, the first step being the
determination of the type of data distribution for each parameter
studied, and the second being the analysis of the effects of the
independent variables. The first step used the Kolmogorov-Smirnov test,
and distributions of data were found to be log normal in all cases.
Using then the logarithmic transformation of data, the effects of
independent variables were first assessed by analysis of variance
(ANOVA). When the latter disclosed nonrandom variations, significant
differences between groups were identified by the Scheffe post hoc
test. Unless stated otherwise, the level of significance was set at
P values of <0.05. These analyses were made using
STATISTICA (Statsoft, Tulsa, Okla.). Correlations were made and plotted
using GraphPad InStat (GraphPad Software, San Diego, Calif.).
Materials.
Gentamicin, netilmicin, and amikacin were the
injectable products distributed in Belgium for human clinical use as
Géomycine and Nétromycine (both from Schering-Plough Labo,
Heist-op-den-Berg, Belgium) and Amukin (Bristol Italiana Sud, S.P.A.,
Latina, Italy), respectively. Isepamicin was an investigational
material for clinical trials (isepamicin sulfate; 250 mg/ml; solution
for intravenous-intramuscular injection; batch 35684-038;
Schering-Plough S.A., Brussels, Belgium). Unless specified otherwise,
all other products and reagents were purchased from established
commercial suppliers and were either of analytical grade or certified
as fit for the projected purpose by the provider.
 |
RESULTS |
As shown in Table 2, a clear-cut
phospholipidosis (assessed by the measurement of cortical phospholipid
content and of urinary phospholipid excretion) was observed in all
animals treated for 10 days with 10 mg of gentamicin per kg. Yet, these
animals did not suffer from kidney dysfunction as revealed by the
measurement of their serum creatinine and BUN. When the gentamicin dose
was raised to 20 mg/kg, no further increase but rather a trend toward a
decrease of the cortical phospholipid content was seen with, however, a
large variation among animals. By contrast, phospholipiduria was
clearly dose dependent in the range investigated. The mean values of
serum creatinine and BUN were elevated in animals treated with 20 mg/kg, but the overall statistical analysis failed to disclose a
significant effect of the treatment because of the large variations
seen. Nevertheless, it was clear that some animals had developed
definite renal dysfunction and that the dose interval chosen for
gentamicin in this experiment clearly spanned the threshold zone
separating the subtoxic alterations from those causing the onset of
acute tubular necrosis and acute renal failure. Table 2 also shows that
netilmicin, as expected, induced a more severe phospholipidosis
(assessed by the assay of cortical phospholipids and phospholipiduria)
than did gentamicin but did not cause significant kidney dysfunction
since all values of BUN or creatinine remained within the range of
controls.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Cortical (drug content and phospholipids), urinary
phospholipiduria, and serum (creatinine and BUN) parameters in
control rats and in rats treated with gentamicin and netilmicin
|
|
The morphological appearance of the cortex of the animals treated at
the two dosages of gentamicin is shown in Fig.
1. At 10 mg/kg, the tubules looked
essentially normal when sections stained with hematoxylin and eosin
were examined at low to medium magnification. Close examination of
these sections at high magnification, however, revealed the appearance
of cells with alterations typical of apoptosis (cell shrinkage
and cytoplasm eosinophilia and presence of a small and shrunken nucleus
with chromatin condensation [Fig. 1A]). The use of the periodic
acid-Schiff reaction confirmed that these cells were almost exclusively
found in proximal tubules (data not shown). The nuclear alterations
characteristic of apoptosis were more clearly visible after
using the Brachet technique (methyl green-pyronine staining [Fig.
1B]). When the daily dose of gentamicin was increased to 20 mg/kg,
apoptotic figures became more frequent (Fig. 1C and D) and, at
the same time, necrotic tubules were clearly and unambiguously seen in
several parts of the cortex (Fig. 1C). Apoptotic cells were most often
found in tubule sections that otherwise looked unremarkable but were
also observed in necrotic tubules. In parallel with these conventional
staining techniques, we examined kidney sections after in situ
immunohistochemical demonstration of DNA fragmentation (TUNEL
technique). As shown in Fig. 2,
scattered, peroxidase-labeled nuclei could easily be detected over the
entire cortex from all treated animals, due to their brownish
appearance contrasting with the light background (Fig. 2B and C). Most
of these labeled nuclei were seen in proximal tubule epithelium, but
some were also observed in the lumen. Sections from control animals
showed only a very few labeled nuclei (Fig. 2A).

View larger version (162K):
[in this window]
[in a new window]
|
FIG. 1.
Light microscopy appearance of paraffin sections of
kidney cortex. (A and C) Sections stained with hematoxylin and eosin;
(B and D) sections stained with methyl green-pyronine (Brachet staining
[8]). Animals were treated with gentamicin for 10 days
(10 [A and B] or 20 [C and D] mg/kg). Single arrows point to cells
showing clear evidence of nuclear alterations related to
apoptosis; the double arrowhead (in panel C) shows a cell with
clear shrinkage and eosinophilia of the cytoplasm; NT (in panel C)
denotes a necrotic tubule. Two mitotic figures are circled in panels B
and D. Bars, 20 µm.
|
|

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 2.
Immunohistochemical demonstration of apoptotic
nuclei in sections of kidney cortical specimens of controls (A) and
animals treated for 10 days with gentamicin at 10 (B) and 20 (C) mg/kg.
Sections were treated for TdT-mediated labeling of fragmented DNA
(TUNEL [19]). Positive nuclei were identified as
shrunken, darkly stained bodies with either a condensed or a fragmented
appearance (arrowheads). Labeling is also detected in small granules
which probably originate from the disruption of an apoptotic
nucleus (arrows). When these granules occurred in clusters, only one
count was recorded in the quantitative analysis (Fig. 3). Bars, 20 µm.
|
|
Having thus demonstrated qualitatively by both conventional histology
and TUNEL the occurrence of apoptosis in the kidney cortex of
animals treated with gentamicin, we undertook a quantification of this
process in comparison with netilmicin. Figure
3 shows the results obtained with TUNEL.
Although there was a fair degree of variability among individual
animals at the highest dose of gentamicin (20 mg/kg), the results
clearly showed a dose dependency of the apoptotic process, with
values reaching up to 240 times those of control animals. A clear-cut
response was also noted for netilmicin but to a markedly lesser extent
than for gentamicin. The occurrence of the apoptotic process
was also quantitated using methyl green-pyronine staining. Figure
4 shows that a highly significant correlation was obtained between the values given by these two techniques, indicating that the variation recorded for the
apoptotic response was linked to a variability among animals
and not to the technique used. Yet, about twice as many
apoptotic figures were scored using the TUNEL technique as were
scored by the methyl green-pyronine staining method, suggesting a major
difference in the sensitivities of the two methods (see Discussion).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Enumeration of apoptotic nuclei observed in
cortex sections after application of TUNEL (Fig. 2). Open circles,
control animals; filled squares, animals treated for 10 days with
gentamicin (G); filled triangles, animals treated with netilmicin (N).
Each point refers to the pooled counts of one individual animal
(n = 6 in each group). Statistical analysis (ANOVA
followed by Scheffe post hoc test with P < 0.05): a,
significantly higher than control; b, significantly higher than the
lower dose; c, significantly lower than the other aminoglycoside at the
same dosage.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 4.
Correlation between the frequency of apoptotic
nuclei detected by TdT-mediated labeling of fragmented DNA (TUNEL) and
revealed by methyl green-pyronine (Brachet staining) in control animals
and in animals treated for 10 days with gentamicin at 10 or 20 mg/kg
(r = 0.89; n = 18; P < 0.001).
|
|
We knew from a previous study (38) that gentamicin, at the
dose of 10 mg/kg, induces a marked proliferative response in kidney
cortex. This reaction was therefore quantitated in the present study
using the [3H]thymidine incorporation approach to draw
quantitative correlations with the apoptotic process. Figure
5 shows that a large number of labeled
nuclei could easily be observed in both the proximal tubules and
the interstitium of gentamicin-treated rats. Using the criterium of
3H incorporation in cortical DNA (Fig.
6), we noted that the response was
highly variable but nevertheless clearly dose dependent (this variability was already noted in earlier studies [38]
and was shown to result from true variation among treated animals
in their ability to incorporate [3H]thymidine in cortical
tissue [54]). A marked difference between gentamicin-treated and netilmicin-treated animals was also
observed. A reasonable correlation was obtained when comparing the
biochemical data (DNA radioactivity) with the enumeration of cells
labeled by histoautoradiography in the kidney cortex of the same
animals. Finally, Fig. 7 shows that
there was a statistically significant correlation between the
proliferative process (quantitated by either the measurement of the
cortical DNA radioactivity or the enumeration of labeled cells
after histoautoradiography) and the apoptotic
response (quantitated by TUNEL). The statistical analysis suggested,
however, that the correlation was not linear.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 5.
Light microscopy appearance of cortex sections processed
for histoautoradiography. Animals were treated for 10 days with
gentamicin (10 [A] or 20 [B] mg/kg). Bars, 20 µm. Each animal
received 200 µCi of [3H]thymidine 1 h before
sacrifice for the demonstration of DNA synthesis in S-phase cells
(arrowheads).
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
Determination of the DNA specific radioactivity in renal
tissue cortex. Open circles, controls; filled squares, animals treated
for 10 days with gentamicin (G); filled triangles, animals treated with
netilmicin (N). Each animal received an intraperitoneal injection of
200 µCi of [3H]thymidine 1 h before sacrifice.
Each symbol refers to an individual animal (n = 6 in
each group). Statistical analysis (ANOVA followed by Scheffe post hoc
test with P < 0.05): a, significantly higher than
control; b, significantly higher than the lower dose; c, significantly
lower than the other aminoglycoside at the same dosage.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 7.
Correlation between cortical DNA radioactivity (A) or
frequency of labeled cells in cortex (B) and apoptosis
(detected by TUNEL) in controls and in animals treated for 10 days with
gentamicin at 10 or 20 mg/kg. Curvilinear, polynomial functions were
fitted by GraphPad software (for panel A, r = 0.90, n = 36, and P < 0.01; for panel B, r = 0.88, n = 18, and P < 0.01) after a first
analysis disclosed a statistically significant nonlinear
relationship.
|
|
To further delineate a potential relationship between all changes
demonstrated so far, we examined the time dependence of their
occurrence by treating animals for both 4 and 10 days. We used only
gentamicin (to obtain large responses for all criteria) but selected
the low dose (10 mg/kg) to fully exclude the possibility of causing
extended necrosis. Results presented in Fig.
8 clearly show that, while drug
accumulation and development of cortical phospholipidosis and
phospholipiduria proceeded in parallel and almost linearly with
time, both DNA synthesis and apoptosis were delayed events with
only minimal changes detected at day 4 compared to what was seen at day
10. Serum creatinine was only minimally increased at the end of the
treatment. In a final series of experiments, we compared gentamicin and
netilmicin to amikacin and isepamicin at an equitherapeutic dose. We
selected again the low dose of gentamicin (10 mg/kg) and set,
accordingly, the doses of amikacin and isepamicin at 40 mg/kg, based on
their corresponding dosage ratios to gentamicin in human clinical use.
Netilmicin was also included to complete the comparison. The treatment
period was set at 10 days to allow for the potential development of all
changes while remaining within acceptable clinical criteria of
treatment duration. As shown in Fig.
9, amikacin and isepamicin (i)
accumulated to lower levels than gentamicin and netilmicin in the
kidney cortex in spite of their higher dosage, (ii) caused a milder
phospholipidosis as assessed by the two criteria of cortical
phospholipid content and phospholipiduria, (iii) caused only a modest
increase in cortical DNA radioactivity, and (iv) caused only minimal
apoptosis (all values for both amikacin- and isepamicin-treated
animals were statistically different from those of gentamicin- and
netilmicin-treated ones). No change in renal function was seen for all
drugs.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 8.
Cortical drug content, cortical total
phospholipids, urinary excretion of phospholipids, DNA specific
radioactivity, apoptotic nuclei in renal cortex (TUNEL), and
serum creatinine in rats treated receiving saline (controls) or
gentamicin at 10 mg/kg for 4 or 10 days. Values are means ± standard deviations (n = 6 in each group). Symbols with
different letters in each graph indicate values significantly different
from each other based on statistical analysis by ANOVA followed by
Scheffe post hoc test (P < 0.05). prot., protein.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 9.
Cortical drug content, cortical total phospholipids,
urinary excretion of phospholipids, DNA specific radioactivity in renal
cortex, apoptotic cells in cortex sections (TUNEL), and serum
creatinine in rats treated with saline (controls) or with gentamicin
(10 mg/kg), netilmicin (10 mg/kg), amikacin (40 mg/kg), or isepamicin
(40 mg/kg) for 10 days. Values are means ± standard deviations
(n = 6 in each group). Groups with different letters
are significantly different from each other based on statistical
analysis by ANOVA followed by Scheffe post hoc test (P < 0.05). prot., protein.
|
|
Finally, we tested whether apoptosis and DNA synthesis were
correlated at the level of all individual animals used to generate the
data of Fig. 9. Figure 10 shows that
the DNA specific radioactivity and TUNEL were indeed correlated in a
nonlinear fashion in an imperfect but nevertheless significant manner.
Similarly, significant, nonlinear correlations were obtained when using
the data from the enumeration of S-phase cells to evaluate the
proliferative process or when assessing apoptosis by methyl
green-pyronine staining (data not shown).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 10.
Correlation between apoptotic cells (TUNEL) and
tubular proliferation (DNA specific radioactivity) in control animals
and all animals treated with aminoglycosides (gentamicin, netilmicin,
amikacin, and isepamicin) for 10 days. Data and treatments are those
used for Fig. 9. A curvilinear, polynomial function was fitted by
GraphPad software (r = 0.69; n = 18; P < 0.01) after a first analysis disclosed a statistically significant
nonlinear relationship.
|
|
 |
DISCUSSION |
Low multiples of the human therapeutic doses of aminoglycosides
have long been known to cause an array of tubular alterations without
signs of extended necrosis and overt tubular dysfunction (48). These alterations were therefore considered by many
observers to be unrelated to toxicity defined by histopathological
damage (mainly cell death) and alteration of kidney function (decrease of glomerular filtration) (20). Yet, our observation that
low-dose treatment is associated with a highly significant increase in cellular proliferation of cortical cells (proximal tubules and interstitium [38]), a process typically considered as
denoting tissue repair and inflammation, has cast doubt on the benign
character of these alterations (39). The present data now
provide unambiguous, quantitative evidence that proximal tubular
epithelium actually undergoes a marked process of nonnecrotic cell
death, namely, apoptosis, upon exposure to gentamicin at these
low multiples of the clinical doses. The morphological techniques that
we have used clearly identify the characteristic changes associated
with the apoptotic process, namely, a nuclear condensation and
fragmentation, together with a shrinkage of the cell body, an
eosinophilia of the cytoplasm, and the characteristic cleavage of DNA
(demonstrated in situ by the TUNEL technique). The lower incidence of
apoptotic cells or clusters of apoptotic bodies
detected by Brachet staining than by the TUNEL approach can probably be
accounted for by the fact that the former detects cells where chromatin
has undergone marked condensation and the cytoplasm has been profoundly
modified, corresponding to a late stage in apoptosis, whereas
the latter allows one to label all nuclei in which DNA has been
fragmented, i.e., at an earlier stage of the apoptotic process.
Although transcription and RNA splicing can to some extent interfere
with the TUNEL method and lead to an overestimation of
apoptotic cells (35), we believe that the
apoptotic process present here is probably more extensive than
can be evidenced by our approaches. Apoptotic cells, indeed, display
changes in surface-exposed sugars and modifications of phospholipid
transversal distribution in plasma membrane, together with an increase
in vitronectin content (17, 57, 58), that ensure their
recognition and swift engulfment by adjacent cells (59).
Apoptotic cells, and damaged tubular cells in general, quickly detach
from the basement membrane and are shed in the urine (55, 56,
66). All these cells will escape detection in tissue sections.
Despite these uncertainties concerning the actual frequency of
apoptotic cells, it is probably safe to say that
apoptosis induced by gentamicin in proximal tubular epithelium of kidney is widespread and develops in a dose-dependent fashion. The
data therefore indicate that apoptosis is clearly part of the
array of early changes occurring in renal tissue after treatment with
aminoglycosides at low doses, i.e., in the absence of detectable necrosis and functional alterations. We also show that
apoptosis and necrosis can simultaneously occur in proximal
tubules when the dosage of gentamicin is moderately increased (20 mg/kg). The observations reported here are therefore of a different
nature than those of Nouwen et al. (51), who reported the
occurrence of apoptosis in distal segments of the nephron after
induction of acute necrosis in proximal tubules by massive gentamicin
dosage (400 mg/kg for 2 days).
Apoptosis plays a major role in kidney embryogenesis, resulting in
large-scale cell death during development (12). By contrast, in the adult and under normal circumstances, evidence of
apoptosis is seldom found in the kidney, where the rate of cell
turnover is very low. However, there are a number of documented cases
related to kidney insult in both pathology and toxicology where the
renal tissue, in particular the tubular epithelium, exhibits a
substantial increase of apoptotic cells (13, 14).
Thus, apoptosis is clearly involved in ischemic renal atrophy
(22) and in the recovery of tubular epithelium after
temporary ischemia (62). The intercalating anticancer agents
doxorubicin and mitoxantrone have also been found to induce
apoptosis in renal tubule epithelium (25). At a low
concentration, cisplatin, another antitumor drug well known for its
renal toxicity, causes apoptosis in cultured proximal tubular
cells (41). Subchronic cadmium intoxication of kidney is
also associated with cell apoptosis occurring in the
absence of necrosis in the S3 segment of proximal tubules
(65). Interestingly enough, the frequency of
apoptotic cells in that model evolves in parallel with that of
S-phase cells, exactly as demonstrated in the present study.
We may at this stage only speculate on the mechanisms by which
aminoglycosides, and gentamicin in particular, cause apoptosis in proximal tubules. It is currently acknowledged that the process leading to apoptosis can be divided into two major phases
(40), namely, the commitment phase and the execution phase.
The commitment phase is reversible and determines whether or not a cell
will undergo apoptosis. This phase can be triggered by a
variety of external or internal stimuli, the influence of which is now
viewed as creating inappropriate signals in a given context. This phase is under the control of an intricate network of regulating systems, most of them also involved in cellular physiological processes distinct
from apoptosis. It is during the execution phase, which is
irreversible, that the cell exhibits the various morphological and
biochemical changes typical of apoptosis, including chromatin compaction and internucleosomal DNA cleavage. Despite the fact that
apoptosis can result from exposure to a wide variety of
stimuli, the execution phase displays a remarkable similarity
irrespective of the cell type or apoptosis inducer and is
probably mediated by a common pathway. Our current knowledge of the
renal disposition of aminoglycosides suggests that these drugs could
act upon either phase of the apoptotic process.
Likely mechanisms related to the commitment phase are (i) a direct
effect of aminoglycosides on membranes, especially the brush border
membrane causing inhibition of phosphatidylinositol phospholipase C
and/or impairment of protein kinase C, both processes likely to lead to
apoptosis (47, 61); and (ii) a perturbation of
mitochondrial integrity leading to the release of caspase-activating proteins (23). The former series of mechanisms, which
essentially rely on direct contact between drug and membrane, are
demonstrable upon exposure to aminoglycosides (24, 42, 46,
60). In our opinion, however, an effect of gentamicin at this
level is difficult to reconcile with the fact that apoptosis,
although already detectable at day 4, becomes particularly prominent
only at a later stage (Fig. 8). This suggests that it is not the mere contact but the accumulation of the gentamicin within kidney cortex which actually causes, directly or indirectly, apoptosis.
Gentamicin accumulated within cells has been shown to interact with
mitochondria, causing disruption of electron transport and a drop in
ATP (63, 75, 76), and these changes could trigger one or
several of the recently described mitochondrial signals involved in the
commitment phase of apoptosis (23). However, most if
not all metabolic effects of aminoglycosides on mitochondria have been
shown to occur after cell death (77).
It is tempting to speculate that aminoglycosides act at the execution
phase by disrupting lysosomes (following their swelling through
phospholipidosis) and provoking the release of cysteine proteases
capable of activating caspase-3 (30), a key effector in the
execution phase of apoptosis (16). This process,
which was already proposed to account for gentamicin-induced cellular necrosis (37, 71) and appears to operate in other cases of apoptosis (9), would nicely explain (i) the delay in
the onset of apoptosis (since a threshold in lysosomal dilation
is probably necessary to cause rupture [70]), (ii) the
self-limiting character of the cortical phospholipidosis (through
sloughing of phospholipid-laden cells), and (iii) the more favorable
behavior of amikacin and isepamicin than of gentamicin (mediated by
both their lower accumulation [this study] and their lesser
inhibitory potential toward lysosomal phospholipases [11,
72]). Yet, a key role of lysosomal alterations in eliciting
apoptosis is difficult to reconcile with the divergent effects
of gentamicin and netilmicin on apoptosis and their common behavior with respect to phospholipidosis. In the absence of further characterization of the precise process ongoing with netilmicin, the
role of lysosomal alterations must therefore remain unsettled with
respect to the onset of apoptosis. Generally speaking, a more
extensive analysis of the toxicological behavior of netilmicin is
warranted, since this aminoglycoside shows a remarkably low overall
toxicity in animals upon acute exposure at large doses (29, 53,
64) but not with chronic treatments at low doses (26).
The toxicological implications of our observations need to be
critically examined. First, the doses of 10 to 20 mg/kg for gentamicin
and netilmicin and of 40 mg/kg for amikacin and isepamicin which were
used in this study can probably be considered low multiples of the
corresponding human doses. They actually can be considered to provide a
total drug exposure (in terms of area under the serum concentration-time curve) lower than or similar to what is observed in
humans treated with the recommended clinical doses of these antibiotics
(20) (Table 1), taking into consideration the difference in
drug elimination half-lives between rats (
30 min) and humans (
120
min). The present data are, therefore, likely to be of immediate clinical relevance and may provide the basis for future investigations in humans. Second, the loss of tubular cells by apoptosis can probably be viewed as a mechanism of tissue damage, and more extensive studies, comparing a large array of aminoglycosides with different established toxicities or using various nephroprotectants
(48), would certainly be useful in this context. Yet, one
may also argue that apoptosis is a favorable event insofar as
it results in an early and swift elimination of those cells the
viability of which is compromised, thereby allowing an efficient
nephrogenic repair that prevents the denudation of the tubular basement
membrane. The fact that netilmicin, amikacin, and isepamicin, all of
which have a better safety profile than gentamicin (48),
also cause less apoptosis pleads strongly, however, for a
pejorative view of aminoglycoside-induced apoptosis. Third, the
fact that a moderately large dose of gentamicin (20 mg/kg) induces both
apoptosis and necrosis actually suggests the existence of two
distinct mechanisms of cytotoxicity which could be entirely different
but could also be related to a limited versus a massive alteration of a
common target. Finally, it now becomes almost certain that the sizeable increase of DNA synthesis detected in the absence of necrosis in
tubular epithelium after treatment of animals with low doses of
aminoglycosides results from cellular proliferation in response to
apoptosis and compensates for the loss of epithelial cells. As
shown earlier, labeled cells seen in tubular epithelium after [3H]thymidine pulse appear indeed in tubules displaying
signs of regeneration and the extent of DNA labeling in cortex matches the abundance of dedifferentiated cells (38, 67). Yet, we cannot exclude the partial involvement of a DNA repair process associated with apoptosis itself. The statistical analysis
revealed that the correlation between the increase in DNA synthesis and apoptosis is not linear, with a more intense cellular
proliferation than anticipated at large doses. As discussed above, this
observation may merely indicate that the extent of apoptosis is
underestimated at large doses because of the swift loss of
apoptotic cells from the epithelium. It may, however, also
suggest that apoptosis is associated with the release of
mitogenic factors which are expected to cause a more than directly
proportionate effects (18). In this context, the peritubular
proliferation which is also observed and has been fully documented and
quantitated in previous studies conducted with the same low doses of
aminoglycosides (38, 67) is probably highly indicative of
such a mitogenic effect caused by tubular injury, since there is no
evidence that aminoglycosides cause direct interstitial damage.
 |
ACKNOWLEDGMENTS |
This work was supported by a fellowship (Aides aux Etudes)
to M. El Mouedden and a grant-in-aid to the Unité de
Pharmacologie Cellulaire et Moléculaire from the French nonprofit
organization Vaincre les Maladies Lysosomales,
Ozoir-la-Ferrière, France, and grants from the Belgian Fund
for Medical Scientific Research (grant no. 3.4516.94), and the
Actions de Recherches Concertées (contract no. 94/99-172) of the
Direction Générale de la Recherche Scientifique
Communauté Française de Belgique. G. Laurent
and M.-P. Mingeot-Leclercq are Senior Research Associate and Research Associate, respectively, of the National Fund for Scientific Research (Belgium).
M. R. Dujardin provided technical assistance for the histological
studies, and M. Philippe provided access to clinical laboratory facilities for the measurement of serum creatinine and BUN.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Unité de
Pharmacologie Cellulaire et Moléculaire, Université
Catholique de Louvain, UCL 73.70 Avenue E. Mounier 73, B-1200 Brussels,
Belgium. Phone: 32-2-764.73.75. Fax: 32-2-764.73.73. E-mail:
elmouedden{at}facm.ucl.ac.be.
 |
REFERENCES |
| 1.
|
Alison, M. R., and C. E. Sarraf.
1995.
Apoptosis: regulation and relevance to toxicology.
Hum. Exp. Toxicol.
14:234-247[Abstract/Free Full Text].
|
| 2.
|
Aoshiba, K.,
A. Nagai, and K. Konno.
1995.
Erythromycin shortens neutrophil survival by accelerating apoptosis.
Antimicrob. Agents Chemother.
39:872-877[Abstract].
|
| 3.
|
Arends, M. J., and A. H. Wyllie.
1991.
Apoptosis: mechanisms and roles in pathology.
Int. Rev. Exp. Pathol.
32:2523-2541.
|
| 4.
|
Bartels, H.,
M. Böhmer, and C. Heierli.
1972.
Serum Kreatininbestimmung ohne Enteiweissen.
Clin. Chim. Acta
37:193-197[CrossRef][Medline].
|
| 5.
|
Bartlett, G. R.
1959.
Phosphorus assay in column chromatography.
J. Biol. Chem.
234:466-468[Free Full Text].
|
| 6.
|
Bennett, W. M.,
C. E. Plamp,
D. N. Gilbert,
R. A. Parker, and G. A. Porter.
1979.
The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure.
J. Infect. Dis.
140:576-580[Medline].
|
| 7.
|
Bligh, E. G., and W. J. Dyer.
1959.
A rapid method of total lipid extraction and purification.
Can. J. Biochem. Physiol.
37:911-917.
|
| 8.
|
Brachet, J.
1953.
The use of basic dyes and ribonuclease for the cytochemical detection of ribonucleic acid.
Q. J. Microsc. Sci.
94:1-10.
|
| 9.
|
Brunk, U. T.,
H. Dalen,
K. Roberg, and H. B. Hellquist.
1997.
Photooxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts.
Free Radic. Biol. Med.
23:616-626[CrossRef][Medline].
|
| 10.
|
Buja, L. M.,
M. L. Eigenbordt, and E. H. Eigenbordt.
1993.
Apoptosis and necrosis: basic types and mechanisms of cell death.
Arch. Pathol. Lab. Med.
117:1208-1215[Medline].
|
| 11.
|
Carlier, M. B.,
G. Laurent,
P. J. Claes,
H. J. Vanderhaeghe, and P. M. Tulkens.
1983.
Inhibition of lysosomal phospholipases by aminoglycoside antibiotics: in vitro comparative studies.
Antimicrob. Agents Chemother.
23:440-449[Abstract/Free Full Text].
|
| 12.
|
Coles, H. S. R.,
J. F. Burne, and M. C. Raff.
1993.
Large scale normal cell death in the developing rat kidney and its reduction by epidermal growth factor.
Development
118:777-784[Abstract].
|
| 13.
|
Conaldi, P. G.,
L. Biancone,
A. Bottelli,
A. Wade-Evans,
L. C. Racusen,
M. Boccellino, and A. Toniolo.
1998.
HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation.
J. Clin. Investig.
102:2041-2049[Medline].
|
| 14.
|
Davis, M. A., and D. H. Ryan.
1998.
Apoptosis in the kidney.
Toxicol. Pathol.
26:810-825[Abstract/Free Full Text].
|
| 15.
|
DiGiorgio, J.
1974.
Nonprotein nitrogenous constituents, p. 503-564.
In
R. J. Henry, D. C. Cannon, and J. W. Winkelman (ed.), Clinical chemistry: principles and techniques, 2nd ed. Harper and Row Publishers, Inc., New York, N.Y.
|
| 16.
|
Enari, M.,
H. Sakahira,
H. Yokoyama,
K. Okawa,
A. Iwamatsu, and S. Nagata.
1998.
A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD.
Nature
391:43-50[CrossRef][Medline].
|
| 17.
|
Fadok, V. A.,
D. R. Voelker,
P. A. Campbell,
J. J. Cohen,
D. L. Bratton, and P. M. Henson.
1992.
Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages.
J. Immunol.
148:2207-2216[Abstract].
|
| 18.
|
Fine, L. G.,
M. R. Hammerman, and H. E. Abboud.
1992.
Evolving role of growth factors in the renal response to acute and chronic disease.
J. Am. Soc. Nephrol.
2:1163-1170[Abstract].
|
| 19.
|
Gavrieli, Y.,
Y. Sherman, and S. A. Ben-Sasson.
1992.
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
J. Cell Biol.
119:493-501[Abstract/Free Full Text].
|
| 20.
|
Gilbert, D. N.
1995.
Aminoglycosides, p. 279-306.
In
G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, New York, N.Y.
|
| 21.
|
Gilbert, D. N.
1997.
Editorial response: meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides.
Clin. Infect. Dis.
24:816-819[Medline].
|
| 22.
|
Gobe, G. C., and R. A. Axelsen.
1987.
Genesis of renal tubular atrophy in experimental hydronephrosis in the rat. Role of apoptosis.
Lab. Investig.
56:273-282[Medline].
|
| 23.
|
Green, D. R., and J. C. Reed.
1998.
Mitochondria and apoptosis.
Science
281:1309-1312[Abstract/Free Full Text].
|
| 24.
|
Hagiwara, M.,
M. Inagaki,
K. Kanamura,
H. Ohta, and H. Hidaka.
1988.
Inhibitory effects of aminoglycosides on renal protein phosphorylation by protein kinase C.
J. Pharmacol. Exp. Ther.
244:355-360[Abstract/Free Full Text].
|
| 25.
|
Herman, E. H.,
J. Zhang,
B. B. Hasinoff,
J. R. Clarck, and V. J. Ferrans.
1997.
Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex.
J. Mol. Cell. Cardiol.
29:2415-2430[CrossRef][Medline].
|
| 26.
|
Hottendorf, G. H.,
D. Barnett,
L. L. Gordon,
E. F. Christensen, and H. Madissoo.
1981.
Nonparallel nephrotoxicity dose-response curves of aminoglycosides.
Antimicrob. Agents Chemother.
19:1024-1028[Abstract/Free Full Text].
|
| 27.
|
Ibrahim, S.,
F. Clerckx-Braun,
P. Jacqmin,
J. Donnez,
V. Brulein, and P. M. Tulkens.
1991.
Effect of the schedule of administration of two aminoglycosides, netilmicin and amikacin on urinary phospholipid excretion in humans, p. 93-97.
In
P. H. Bach, N. J. Gregg, M. F. Wilks, and L. Delacruz (ed.), Nephrotoxicity: mechanisms, early diagnosis and therapeutic management. Marcel Dekker, New York, N.Y.
|
| 28.
|
Ibrahim, S.,
P. Van der Auwera,
F. Meunier, and P. M. Tulkens.
1989.
Effect of netilmicin and amikacin on urinary phospholipid excretion in humans.
Arch. Toxicol.
13(Suppl.):413-416.
|
| 29.
|
Igarashi, M.,
J. K. Levy, and J. Jerger.
1978.
Comparative toxicity of netilmicin and gentamicin in squirrel monkeys (Saimiri sciureus).
J. Infect. Dis.
137:476-480[Medline].
|
| 30.
|
Ishisaka, R.,
T. Utsumi,
M. Yabuki,
T. Kanno,
T. Furuno,
M. Inoue, and K. Utsumi.
1998.
Activation of caspase-3-like protease by digitonin-treated lysosomes.
FEBS Lett.
435:233-236[CrossRef][Medline].
|
| 31.
|
Jaffé, M.
1886.
Über den Niederschlag welchen Pikrinsäure in normalen Harn erzeugt und über eine neue Reaktion des Kreatinins.
Z. Physiol. Chem.
10:391-400.
|
| 32.
|
Josepovitz, C.,
R. Levine,
B. Lane, and G. J. Kaloyanides.
1985.
Contrasting effects of gentamicin and mercuric chloride on urinary excretion of enzymes and phospholipids in the rat.
Lab. Investig.
52:375-386[Medline].
|
| 33.
|
Kerr, J. F. R.,
A. H. Wyllie, and A. R. Currie.
1972.
Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics.
J. Cancer
26:239-257.
|
| 34.
|
Kishore, B. K.,
S. Ibrahim,
P. Lambricht,
G. Laurent,
P. Maldague, and P. M. Tulkens.
1992.
Comparative assessment of poly-L-aspartic and poly-L-glutamic acids against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats.
J. Pharmacol. Exp. Ther.
262:424-432[Abstract/Free Full Text].
|
| 35.
|
Kockx, M. M.,
J. Muhring,
M. W. M. Knaapen, and G. R. Y. de Meyer.
1998.
RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis.
Am. J. Pathol.
152:885-888[Abstract].
|
| 36.
|
Lang, H., and C. Liu.
1997.
Apoptosis and hair cell degeneration in the vestibular sensory epithelia of the guinea pig following a gentamicin insult.
Hear. Res.
111:177-184[CrossRef][Medline].
|
| 37.
|
Laurent, G.,
B. K. Kishore, and P. M. Tulkens.
1990.
Aminoglycoside-induced phospholipidosis and nephrotoxicity.
Biochem. Pharmacol.
40:2383-2392[CrossRef][Medline].
|
| 38.
|
Laurent, G.,
P. Maldague,
M. B. Carlier, and P. Tulkens.
1983.
Increased renal DNA synthesis in vivo after administration of low doses of gentamicin to rats.
Antimicrob. Agents Chemother.
24:586-593[Abstract/Free Full Text].
|
| 39.
|
Laurent, G.,
G. Toubeau,
J. A. Heuson-Stiennon,
P. Tulkens, and P. Maldague.
1988.
Kidney tissue repair after nephrotoxic injury: biochemical and morphological characterization.
Crit. Rev. Toxicol.
19:147-183[Medline].
|
| 40.
|
Lieberthal, W., and J. S. Levine.
1996.
Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury.
Am. J. Physiol.
271:F471-F488.
|
| 41.
|
Lieberthal, W.,
V. Triaca, and J. Levine.
1996.
Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs necrosis.
Am. J. Physiol.
270:F700-F708[Abstract/Free Full Text].
|
| 42.
|
Lipsky, J. J., and P. S. Lietman.
1982.
Aminoglycoside inhibition of a renal phosphatidylinositol phospholipase C.
J. Pharmacol. Exp. Ther.
220:287-292[Abstract/Free Full Text].
|
| 43.
|
Lockshin, R. A., and C. M. Williams.
1965.
Programmed cell death. I. Cytology of the degeneration in the intersegmental muscles of peryi silkmoth.
J. Insect Physiol.
11:123-133[CrossRef][Medline].
|
| 44.
|
Lockshin, R. A., and Z. Zakeri.
1991.
Programmed cell death and apoptosis, p. 47-60.
In
L. D. Tomei, and F. O. Coppe (ed.), Apoptosis: the molecular basis of cell death. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 45.
|
Lowry, O. H.,
N. J. Rosebrough,
A. L. Farr, and R. J. Randall.
1951.
Protein measurement with the Folin phenol reagent.
J. Biol. Chem.
193:265-275[Free Full Text].
|
| 46.
|
Marche, P.,
B. Olier,
A. Girard,
J. P. Fillastre, and J. P. Morin.
1987.
Aminoglycoside-induced alterations of phosphoinositide metabolism.
Kidney Int.
31:59-64[Medline].
|
| 47.
|
Miao, J. Y.,
K. Kaji,
H. Hayashi, and S. Araki.
1997.
Inhibitors of phospholipase promote apoptosis of human endothelial cells.
J. Biochem.
121:612-618[Abstract/Free Full Text].
|
| 48.
|
Mingeot-Leclercq, M. P., and P. M. Tulkens.
1999.
Aminoglycosides: nephrotoxicity.
Antimicrob. Agents Chemother.
43:1003-1012[Free Full Text].
|
| 49.
|
Mingeot-Leclercq, M. P.,
Y. Glupczynski, and P. M. Tulkens.
1999.
Aminoglycosides: activity and resistance.
Antimicrob. Agents Chemother.
43:727-737[Free Full Text].
|
| 50.
|
Nagakawa, T.,
H. Yamane,
M. Takayama,
K. Sunami, and Y. Nakai.
1998.
Apoptosis of guinea pig cochlear hair cells following chronic aminoglycoside treatment.
Eur. Arch. Otorhinolaryngol.
255:127-131[CrossRef][Medline].
|
| 51.
|
Nouwen, E. J.,
W. A. Verstrepen,
N. Buyssens,
M.-Q. Zhu, and M. E. De Broe.
1994.
Hyperplasia, hypertrophy, and phenotypic alterations in the distal nephron after acute proximal tubular injury in the rat.
Lab. Investig.
70:479-493[Medline].
|
| 52.
|
Parker, R. A.,
W. H. Bennett, and G. A. Porter.
1982.
Animal models in the study of aminoglycoside nephrotoxicity, p. 235-267.
In
A. Whelton, and H. C. Neu (ed.), The aminoglycosides: microbiology, clinical use and toxicology. Marcel Dekker, Inc., New York, N.Y.
|
| 53.
|
Parker, R. A.,
D. N. Gilbert,
D. C. Houghton,
G. A. Porter, and W. M. Bennett.
1980.
Comparative nephrotoxicities of high-dose netilmicin and tobramycin in rats.
Antimicrob. Agents Chemother.
18:346-348[Abstract/Free Full Text].
|
| 54.
|
Porter, G. A.,
G. Laurent,
P. Maldague, and P. M. Tulkens.
1984.
Gentamicin-induced stimulation of DNA synthesis in rat kidney cortex. Comparison between in vivo and in vitro models.
Toxicol. Lett.
23:205-213[CrossRef][Medline].
|
| 55.
|
Racusen, L.
1998.
Epithelial cell shedding in acute renal injury.
Clin. Exp. Pharmacol. Physiol.
25:273-275[Medline].
|
| 56.
|
Racusen, L. C.,
B. A. Fivush,
Y. L. Li,
I. Slatnik, and K. Solez.
1991.
Dissociation of tubular cell detachment and tubular cell death in clinical and experimental acute tubular necrosis.
Lab. Investig.
64:546-556[Medline].
|
| 57.
|
Savill, J.,
I. Dransfield,
N. Hogg, and C. Haslett.
1990.
Vitronectin receptor mediated phagocytosis of cells undergoing apoptosis.
Nature
343:170-173[CrossRef][Medline].
|
| 58.
|
Savill, J. S.,
V. Fadok,
P. Henson, and C. Haslett.
1993.
Phagocyte recognition of cells undergoing apoptosis.
Immunol. Today
14:131-136[CrossRef][Medline].
|
| 59.
|
Savill, J. S.,
P. M. Henson, and C. Haslett.
1989.
Phagocytosis of aged human neutrophils by macrophages is mediated by novel "charge sensitive" recognition mechanism.
J. Clin. Investig.
84:1518-1527.
|
| 60.
|
Schwertz, D. W.,
J. I. Kreisberg, and M. A. Venkatachalam.
1984.
Effects of aminoglycosides on proximal tubule brush border membrane phosphatidylinositol-specific phospholipase C.
J. Pharmacol. Exp. Ther.
231:48-55[Abstract/Free Full Text].
|
| 61.
|
Serlachius, E.,
J. Svennilson,
M. Schalling, and A. Asperia.
1997.
Protein kinase C in the developing kidney: isoform expression and effects of ceramide and PKC inhibitors.
Kidney Int.
52:901-910[Medline].
|
| 62.
|
Shimizu, A., and N. Yamada.
1993.
Apoptosis and cell desquamation in repair process of ischemic tubular necrosis.
Mol. Pathol.
64:171-180.
|
| 63.
|
Simmons, C. F.,
J. Ronald,
T. Bogusky, and H. D. Humes.
1980.
Inhibitory effects of gentamicin on renal mitochondrial oxidative phosphorylation.
J. Pharmacol. Exp. Ther.
214:709-715[Free Full Text].
|
| 64.
|
Szot, R. J.,
G. McCormick,
M. Chung,
B. Christie,
E. Weinberg, and E. Schwartz.
1980.
Comparative toxicity of netilmicin and tobramycin in dogs.
Toxicol. Appl. Pharmacol.
55:169-178[CrossRef][Medline].
|
| 65.
|
Tanimoto, A.,
T. Hamada, and O. Koide.
1993.
Cell death and regeneration of renal proximal tubular cells in rats with subchronic cadmium intoxication.
Toxicol. Pathol.
21:341-352[Medline].
|
| 66.
|
Thompson, C. B.
1995.
Apoptosis in the pathogenesis and treatment of disease.
Science
267:1456-1462[Abstract/Free Full Text].
|
| 67.
|
Toubeau, G.,
G. Laurent,
M. B. Carlier,
S. Abid,
P. Maldague,
J. A. Heuson-Stiennon, and P. M. Tulkens.
1986.
Tissue repair in rat kidney cortex after short treatment with aminoglycosides at low doses: a comparative biochemical and morphometric study.
Lab. Investig.
54:385-393[Medline].
|
| 68.
|
Tulkens, P., and A. Trouet.
1978.
The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts.
Biochem. Pharmacol.
27:415-424[CrossRef][Medline].
|
| 69.
|
Tulkens, P.,
G. Laurent,
M. B. Carlier,
G. Toubeau,
J. Heuson-Stiennon, and P. Maldague.
1983.
Comparative study of the alterations induced in rat kidney by gentamicin, dibekacin, netilmicin, tobramycin and amikacin at low doses, p. 30-35.
In
K. H. Spitzy, and K. Karrer (ed.), Proceedings of the 13th International Congress of ChemotherapyVienna, Austria.
|
| 70.
|
Tulkens, P. M.
1986.
Experimental studies on nephrotoxicity of aminoglycosides at low doses: mechanisms and perspectives.
Am. J. Med.
80:105-114[Medline].
|
| 71.
|
Tulkens, P. M.,
M. E. De Broe,
P. Maldague, and J. A. Heuson-Stiennon.
1983.
Lysosomal alterations in aminoglycoside-induced acute renal failure, p. 299-327.
In
K. Solez, and A. Whelton (ed.), Acute renal failure: correlations between morphology and function. Marcel Dekker, New York, N.Y.
|
| 72.
|
Tulkens, P. M.,
M. P. Mingeot-Leclercq,
G. Laurent, and R. Brasseur.
1990.
Conformational and biochemical analysis of the interactions between phospholipids and aminoglycoside antibiotics in relation with their toxicity, p. 63-93.
In
R. Brasseur (ed.), Molecular description of biological membrane components by computer-aided conformational analysis. CRC Press, Inc., Boca Raton, Fla.
|
| 73.
|
Ueda, N., and S. V. Shah.
1994.
Apoptosis.
J. Lab. Clin. Med.
124:169-177[Medline].
|
| 74.
|
Vermes, I., and C. Haanen.
1994.
Apoptosis and programmed cell death in health and disease.
Adv. Clin. Chem.
31:177-246[Medline].
|
| 75.
|
Weinberg, J. M.
1986.
The role of cell calcium overload in nephrotoxic renal tubular cell injury.
Am. J. Kidney Dis.
8:284-291[Medline].
|
| 76.
|
Weinberg, J. M., and H. D. Humes.
1980.
Mechanisms of gentamicin-induced dysfunction of renal cortical mitochondria. I. Effects on mitochondrial respiration.
Arch. Biochem. Biophys.
205:222-231[CrossRef][Medline].
|
| 77.
|
Weinberg, J. M.,
P. G. Harding, and H. D. Humes.
1980.
Mechanisms of gentamicin-induced dysfunction of renal cortical mitochondria. II. Effects on mitochondrial monovalent cation transport.
Arch. Biochem. Biophys.
205:232-239[CrossRef][Medline].
|
Antimicrobial Agents and Chemotherapy, March 2000, p. 665-675, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Chen, H.-H., Sue, Y.-M., Chen, C.-H., Hsu, Y.-H., Hou, C.-C., Cheng, C.-Y., Lin, S.-L., Tsai, W.-L., Chen, T.-W., Chen, T.-H.
(2009). Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant
24: 3042-3049
[Abstract]
[Full Text]
-
Sue, Y.-M., Cheng, C.-F., Chang, C.-C., Chou, Y., Chen, C.-H., Juan, S.-H.
(2009). Antioxidation and anti-inflammation by haem oxygenase-1 contribute to protection by tetramethylpyrazine against gentamicin-induced apoptosis in murine renal tubular cells. Nephrol Dial Transplant
24: 769-777
[Abstract]
[Full Text]
-
Denamur, S., Van Bambeke, F., Mingeot-Leclercq, M.-P., Tulkens, P. M.
(2008). Apoptosis Induced by Aminoglycosides in LLC-PK1 Cells: Comparative Study of Neomycin, Gentamicin, Amikacin, and Isepamicin Using Electroporation. Antimicrob. Agents Chemother.
52: 2236-2238
[Abstract]
[Full Text]
-
Juan, S.-H., Chen, C.-H., Hsu, Y.-H., Hou, C.-C., Chen, T.-H., Lin, H., Chu, Y.-L., Sue, Y.-M.
(2007). Tetramethylpyrazine protects rat renal tubular cell apoptosis induced by gentamicin. Nephrol Dial Transplant
22: 732-739
[Abstract]
[Full Text]
-
Servais, H., Jossin, Y., Van Bambeke, F., Tulkens, P. M., Mingeot-Leclercq, M.-P.
(2006). Gentamicin Causes Apoptosis at Low Concentrations in Renal LLC-PK1 Cells Subjected to Electroporation.. Antimicrob. Agents Chemother.
50: 1213-1221
[Abstract]
[Full Text]
-
Bledsoe, G., Crickman, S., Mao, J., Xia, C.-F., Murakami, H., Chao, L., Chao, J.
(2006). Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant
21: 624-633
[Abstract]
[Full Text]
-
Ward, D. T., Maldonado-Perez, D., Hollins, L., Riccardi, D.
(2005). Aminoglycosides Induce Acute Cell Signaling and Chronic Cell Death in Renal Cells that Express the Calcium-Sensing Receptor. J. Am. Soc. Nephrol.
16: 1236-1244
[Abstract]
[Full Text]
-
Van Bambeke, F., Michot, J.-M., Tulkens, P. M.
(2003). Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother
51: 1067-1077
[Full Text]
-
Ward, D. T., McLarnon, S. J., Riccardi, D.
(2002). Aminoglycosides Increase Intracellular Calcium Levels and ERK Activity in Proximal Tubular OK Cells Expressing the Extracellular Calcium-Sensing Receptor. J. Am. Soc. Nephrol.
13: 1481-1489
[Abstract]
[Full Text]
-
El Mouedden, M., Laurent, G., Mingeot-Leclercq, M.-P., Tulkens, P. M.
(2000). Gentamicin-Induced Apoptosis in Renal Cell Lines and Embryonic Rat Fibroblasts. Toxicol Sci
56: 229-239
[Abstract]
[Full Text]